Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Dr. Reddy’s Laboratories, LTD, Biologics violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Inspects Dr. Reddy’s Laboratories, LTD, Biologics: Form 483 with 4 Citations (September 12, 2025)

At a glance: FDA inspected Dr. Reddy’s Laboratories, LTD, Biologics in India and issued a Form 483 listing 4 inspectional observations following an inspection that concluded 2025-09-12. FDA records classify Dr. Reddy’s Laboratories, LTD, Biologics as a drug substance intermediate manufacturer. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Dr. Reddy’s Laboratories, LTD, Biologics
FEI / inspection ID	3014250111
Inspection end date	September 12, 2025
Citation count	4

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — The Quality Unit has not established adequate procedural controls and oversight to

The Quality Unit has not established adequate procedural controls and oversight to ensure the accuracy of environmental monitoring data. Environmental monitoring data from data collection sheets are manually entered into uncontrolled electronic spreadsheets, which are subsequently used to generate reports and graphical analyses. During the inspection, multiple discrepancies and inaccuracies were identified between the source data and the corresponding reports. Due to inaccurate and incomplete environmental monitoring data, the effectiveness of corrective and preventive actions (CAPA) implemented in response to

Observation 2 — from the Form FDA 483 issued October 2023 cannot be adequately assessed

from the Form FDA 483 issued October 2023 cannot be adequately assessed. Specifically, A. Deviation reports contained inaccurate data on mold recoveries. i. Deviation DV2000016762 report lists inaccurate mold counts data which differ from source data form (FORM-BTO-QC-0108, Doc. Control no. 72). CbTt,RP- B. ~ CbTOO rend Analysis Summary Report for Environmental Monitoring i 0TO-003811, Versio11 1.0, dJJIJ• uvt!J u11 Aμr ii 8, 2025) w11ldi11t!J i11dLLur dlt! udld u11 111ulJ recoveries compared to corresponding deviation reports or discrepancies: ENPl0\'l!EiSI SIGNAT\!Re EMPI..OYEE(S) NA-11£ N-40 m LE (AW or Typt:) DATelSSUEO SEE REVERSE OF THIS PAGE \f olld!llfo~N ..... -~ ,to..... O"IWffl..""'" •i - ·· ..,.,.i.n,..,_.,. ,..u .... - O;g l w~~ed'i,y~thaP, Baikuntha P. Arya( -5 ~: ~ ,O!!.q " "~"" ••~"' Madus hi ni Dharmas ena, Ph .D., Se ni or Pharmaceutical Quality Assessor Baikuntha Aryal, Ph.D., Pha r maceutical Sc i enti st 9/12/2025 Oig,t.t ly SA!JMd by IA»GSONG JIANG5ONG Jll it.NG ·S (Affibt~J 202 206 JIANG -5 (Affiliate) :::;,,.

Observation 3 — The firm failed to establish adequate document control procedures and oversight mechan

The firm failed to establish adequate document control procedures and oversight mechan is ms to ensure appropriate management of written documents. Specifically, The current DOCHUB system permits users to download approved documents in Microsoft Word format without embedded approval signatures. This system configuration creates the potential for unauthorized document modification, as users can alter content and subsequently save documents in PDF format, generating uncontrolled copies. This practice is inconsistent with the firm 's own work instruction document (WI-GLOB-IT-0304, effective July 12, 2024), which restricts export or printing of uncontrolled document copies to authorized document coordinators and system administrators only. Specifically, documents (No. RP-BTO-001232, RP- BTO-001234, RP-BT0-001235, RP-BTO-001237 and RP - BTO -001238) provided in PDF format (in response to records requests pursuant to Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Ac t) di sp layed approval sta tu s but lacked the required approval signatures of reviewing and approving officials and approval dates. ;t.t?tOvt£1SI SIGNATURE EMPLOYEE($) NAME ANO.

Observation 4 — Written documents are inadequate to ensure proper documentation and anal ysis of

Written documents are inadequate to ensure proper documentation and anal ysis of critical manufacturing operations. Specifically, A. Report VALRP- BTO -002395, Summary report for airflow visualization study and assessment of 4 aseptic interventions during vial fillingj <6rt ~(Version 1.0, approved on September 3, 2025), failed to provide a comprehensive analysis of the smoke study videos and contained only a checklist of interventions performed. The report did not adequately evaluate or document E""'-OYEE(S) SIGNATURE EMPI.OYeE(S) NAM E ANO nn.E (PrMt or Ty~) OATE ISSUEO SEE REVERSE OF THIS PAGE Madushini N. ""l'f•"'~.. .,.....,._, o,,.,....v,,, \ Dh.umasena -s Otlr rtfl:i11Ht iJG•)'tit Baikun tha P. Arya! ~.'.;.,"1...,.,.,.....,.•• • -5 Oa1•:202S.tlt1l Ud1:21...0S' l0' Madushini Dharmasena, Ph .D. , Senior Ph a rmaceutical Quality Assessor Baikuntha Arya !, Ph.D., Pharmaceut ical Scientist 9/12/2025 JIANGSONG 0,011,1~ ,,.,..,., JI AHGSOOG Jiangsong Jiang, Ph.D., Jl~ ~-J(il tllh.ltd Pharmaceutical Scientist JIANG -5 (Affiliate) o,,._,,... "'·"•'~•••-()4·'"

Dr. Reddy’s Laboratories, LTD, Biologics’s FDA history

Argus HQ has recorded 1 total FDA action tied to Dr. Reddy’s Laboratories, LTD, Biologics: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Dr. Reddy’s Laboratories, LTD, Biologics violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Dr. Reddy’s Laboratories, LTD, Biologics

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). FDA Inspects Dr. Reddy’s Laboratories, LTD, Biologics: Form 483 with 4 Citations (September 12, 2025). Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-dr-reddy-s-laboratories-ltd-biologics-2025-09-12-3014250111

MLA

"FDA Inspects Dr. Reddy’s Laboratories, LTD, Biologics: Form 483 with 4 Citations (September 12, 2025)." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-dr-reddy-s-laboratories-ltd-biologics-2025-09-12-3014250111.

Chicago

Argus HQ Research. "FDA Inspects Dr. Reddy’s Laboratories, LTD, Biologics: Form 483 with 4 Citations (September 12, 2025)." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/483/fda-483-dr-reddy-s-laboratories-ltd-biologics-2025-09-12-3014250111.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_dr_reddy_s_laboratories_ltd_biologics_2025_09_12_3014250111_2025,
  title = {FDA Inspects Dr. Reddy’s Laboratories, LTD, Biologics: Form 483 with 4 Citations (September 12, 2025)},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-dr-reddy-s-laboratories-ltd-biologics-2025-09-12-3014250111},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗